İKİNCİ TRİMESTER MATERNAL SERUM BELİRTEÇLERİNİN SAĞLIKLI GEBELERDE DOĞUM ZAMANINI ÖNGÖRMEDEKİ ROLÜ

Giriş: Fetal büyüme ve gelişme fetusun genetik yapısının, çevresel faktörlerin, annenin ve plasentanın etkili olduğu multi-fonksiyonel bir durumdur. Bu mekanizmada anne, plasenta ve fetüs tarafından salgılanan hormonlar belirleyici rol oynamaktadır. İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi (Medical Journal of İzmir Hospital) 25 (2): 139-145, 2021 140 İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi (Medical Journal of İzmir Hospital) İkinci trimester anomali taramasında kullanılan belirteçlerinde bu mekanizmada rol aldığı düşünülmektedir. Bu belirteçler başlangıçta sadece risk altındaki gebeyi nöral tüp defektleri açısından araştırmak amacıyla kullanılırken, daha sonra diğer anatomik malformasyonlar, anöploidi ve üçüncü trimester komplikasyonlarının araştırılmasında da kullanılmaya başlanmıştır. Mevcut çalışmalar çoğunlukla kötü prognozu öngörmede belirteçlerin etkinliğini araştırmaktadır. Bizim bu çalışmadaki amacımız ise risk faktörü olmayan sağlıklı gebeliklerin yönetiminde bu belirteçleri incelemek ve doğum haftasını öngörmede, buna bağlı olarak da doğum zamanını planlamada etkinliğini araştırmaktır. Gereç ve Yöntem: 2017-2020 yıllarında hastanemiz Kadın Hastalıkları ve Doğum Kliniğine başvuran üçlü tarama sonucu olan ve hastanemizde doğum yapmış hastaların verileri retrospektif olarak incelendi.Çalışmaya dahil edilen gebelerin yaş, doğum kilosu, obstetrik öyküsü, doğum şekli, bebek doğum kilosu gibi demografik bilgileri ve 3’lü tarama testi belirteçlerinin sonuçlarıhastane kayıtlarından öğrenildi. p0,05). 37 hafta ve öncesi doğum olasılığını öngörmede regresyon analizine göre gebelik yaşı, bebek doğum kilosu ile pozitif yönde istatistiksel olarak anlamlılık gözlendi (p=0,005, p

THE ROLE OF SECOND TRIMESTER MATERNAL SERUM MARKERS; PREDICTING TIME OF DELIVERY IN HEALTHY PREGNANCIES

Introduction: Markers used in second-trimester anomaly screening are also believed to play a role in fetal growthand development.While these markers were initially used only to investigate pregnant women at risk for neural tubedefects, they were later used to examine other anatomical malformations, aneuploidy, and third-trimestercomplications. This study aims to examine these serum markers in managing healthy pregnancies without riskfactors and to investigate the effectiveness of these markers in predicting the birth week and planning the birth time.Material and Method: The data of the patients who were admitted to Gynecology and Obstetrics Clinic of ourhospital and who had given birth in our hospital were retrospectively examined and recorded.Demographic data of patients, such as age, weight at birth, obstetric history, delivery method, gestational weekduring delivery and newborn weight, serum markers of triple screening test were retrospectively obtained from thehospital records.Results: The study included 100 patients. Sixty-six of the patients delivered their babies through cesareansection and 34 by vaginally. A comparison was made between groups according to gestational age, weight ofpregnant women, newborn weight and triple screening test parameters.No significant difference was observedbetween the groups according to screening test serum markers(p>0,05). According to regression analysis,positive statistical significance was obtained between gestational age and newborn weight in predicting the birthprobability at 37 weeks and before (p=0.005, p< 0.0001).Conclusion: As a result, it has been observed that second-trimester screening markers were not significant onpredicting the timing of birth in normal pregnant women. We believe that prospective studies in which onlypatients who had a vaginal delivery and had a history of cesarean section in the pregnant women with startedlabor were included in the study group may change the results.

PDF

___

1. Goto E. Maternal blood biomarkers of placentation to predict low-birth-weight newborns: A Meta-Analysis. J Obstet Gynaecol Can. 2017; 39(8): 635-44.
2. Sayın NC, Canda MT, Ahmet N, Arda S, Süt N, Varol FG. The association of triple marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns. Arch of Gynecol Obstet 2008; 277(1): 47-53.
3. Lambert-Messerlian G, Eklund EE, Chien EK, Rosene-Montella K, Neveux LM, Haddow HRM, et al. Use of first or secondtrimester serum markers, or both, to predict preeclampsia. Pregnancy Hypertasion: Int J Women’s Cardiovasc Health. 2014;
4: 271-8. 4. Dutton PJ, Warrander LK, Roberts SA, Bernatavicius G, Byrd LM, Gaze D et al. Predictors of poor perinatal outcome following maternal perception of reduced fetal movements - a prospective cohort study. PLoS One. 2012; 7(7): e39784.
5. Heazell AE, Whitworth M, Duley L, Thornton JG. Use of biochemical tests of placental function for improving pregnancy outcome. Cochrane Database Syst Rev 2015; (11): CD011202. 6. Towner D, Gandhi S, El Kady D. Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin. Am J Obstet Gynecol 2006; 194(6):1676-82.
7. Genç Z, Balta O, Eren S, Bağlam E. Elevated serum levels of human chorionic gonadotropin and alpha-fetoprotein predicting for development of severe preeclampsia. Turk J Obstet Gynecol 2005; 2(4):305-10.
8. Sirikunalai P, Wanapirak C, Sirichotiyakul S, Tongprasert F, Srisupundit K, Luewan S et al. Associations between maternal serum free beta-human chorionic gonadotropin (β-hCG) levels and adverse pregnancy outcomes. J Obstet Gynaecol 2016; 36(2):178-82.
9. Puntachai P, Wanapirak C, Sirichotiyakul S, Tongprasert F, Srisupundit K, Luewan S et al. Associations between pregnancy outcomes and unexplained high and low maternal serum alpha-fetoprotein levels. Arch Gynecol Obstet 2015; 292(1): 81-5.
10. Santolaya-Forgas J, Jessup J, Burd LI, Prins GS, Burton BK. Pregnancy outcome in women with low mid-trimester maternal serum unconjugated estriol. J Reprod Med 1996; 41(2): 87-90.
11. Schleifer RA, Bradley LA, Richards DS, Ponting NR. Pregnancy outcome for women with very low levels of maternal serum unconjugated estriol on second-trimester screening. Am J Obstet Gynecol 1995; 173(4): 1152–6.
12. Gagnon A, Wilson RD. Obstetrical complications associated with abnormal maternal serum markers analytes. J ObstetGynaecol Can 2008; 30(10): 918-32.
13. Coskun B, Kokanalı D, Simsir C, Coskun B, Gokdemir I E, Colak E et al. Association between second trimester maternal serum markers and birth weight. Fırat Tıp Dergisi/Firat Med J 2019; 24 (1): 42-6
14. Beta J, Bredaki FE, Rodriguez Calvo J, Akolekar R, Nicolaides KH. Maternal serum α-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery. Fetal DiagnTher 2011; 30(2): 88- 93.
15. Kim SM, Yun HG, Kim RY, Chung YH, Cheon JY, Wie JH et al. Maternal serum placental growth factor combined with second-trimester aneuploidy screening to predict small-for-gestation neonates without preeclampsia. Taiwan J Obstet Gynecol 2017; 56(6): 801-5.
16. Settiyanan T, Wanapirak C, Sirichotiyakul S, Tongprasert F, Srisupundit K, Luewan S et al. Association between isolated abnormal levels of maternal serum unconjugated estriol in the second trimester and adverse pregnancy outcomes. J Matern Fetal Neonatal Med 2016; 29(13): 2093-7.
17. Bond DM, Middleton P, Levett KM, Van der Ham DP, Crowther CA, Buchanan BL et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database Syst Rev 2017; 3(3): CD004735.
18. Maso MJ, Gong EJ, Jacobson MS, Bross DS, Heald FP. Anthropometric predictors of low birth weight outcome in teenage pregnancy. J Adolesc Health Care 1988; 9(3): 188-93
19. Nahar S, Mascie-Taylor CGN, Begum HA. Maternal anthropometry as a predictor of birth weight. Public Health Nutr 2007; 10(9): 965-70.